Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

被引：0
|
作者：
R. de Haan
E. van Werkhoven
M.M. van den Heuvel
H. M. U. Peulen
G. S. Sonke
P. Elkhuizen
M. W. M. van den Brekel
M. E. T. Tesselaar
C. Vens
J. H. M. Schellens
B. van Triest
M. Verheij
机构：
[1] Department of Radiation Oncology,Department of Biometrics
[2] The Netherlands Cancer Institute,Department of Thoracic Oncology
[3] The Netherlands Cancer Institute,Department of Medical Oncology
[4] The Netherlands Cancer Institute,Department of Head and Neck Surgery and Oncology
[5] The Netherlands Cancer Institute,Division of Cell Biology
[6] The Netherlands Cancer Institute,Division of Pharmacology
[7] The Netherlands Cancer Institute,Department of Pharmaceutical Sciences
[8] The Netherlands Cancer Institute,undefined
[9] Utrecht University,undefined
来源：
BMC Cancer | / 19卷
关键词：
Radiotherapy; Radiosensitisation; Olaparib; PARP inhibitor; Phase 1; Dose escalation; TITE-CRM; Dose limiting toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca).
    Lee, J.
    Annunziata, C. M.
    Minasian, L. M.
    Zujewski, J.
    Prindiville, S. A.
    Kotz, H. L.
    Squires, J.
    Houston, N. D.
    Ji, J. J.
    Yu, M.
    Doroshow, J. H.
    Kohn, E. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer
    Shah, Payal D.
    Wethington, Stephanie L.
    Pagan, Cheyenne
    Latif, Nawar
    Tanyi, Janos
    Martin, Lainie P.
    Morgan, Mark
    Burger, Robert A.
    Haggerty, Ashley
    Zarrin, Haley
    Rodriguez, Diego
    Domchek, Susan
    Drapkin, Ronny
    Shih, Ie-Ming
    Smith, Simon A.
    Dean, Emma
    Gaillard, Stephanie
    Armstrong, Deborah
    Torigian, Drew A.
    Hwang, Wei-Ting
    Giuntoli, Robert
    Simpkins, Fiona
    GYNECOLOGIC ONCOLOGY, 2021, 163 (02) : 246 - 253
  • [23] PHASE II STUDY OF THE ORAL PARP INHIBITOR OLAPARIB (AZD2281) VERSUS LIPOSOMAL DOXORUBICIN IN OVARIAN CANCER PATIENTS WITH BRCA1 AND/OR BRCA2 MUTATIONS
    Kaye, S.
    Kaufman, B.
    Lubinski, J.
    Matulonis, U.
    Gourley, C.
    Karlan, B.
    Taylor, D.
    Wickens, M.
    Carmichael, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 304 - 304
  • [24] MEDIOLA: An open-label, phase I/II basket study of olaparib (PARP inhibitor) and durvalumab (anti-PD-L1 antibody) Additional breast cancer cohorts
    Domchek, S. M.
    Postel-Vinay, S.
    Im, S-A
    Park, Y. Hee
    Delord, J-P
    Italiano, A.
    Alexandre, J.
    You, B.
    Bastian, S.
    Krebs, M. G.
    Waqar, S.
    Lanasa, M.
    Angell, H. K.
    Tang, M.
    Gresty, C.
    Opincar, L.
    Herbolsheimer, P.
    Kaufman, B.
    CANCER RESEARCH, 2019, 79 (04)
  • [25] Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma
    Fanucci, Kristina
    Pilat, Mary Josephine Paula
    Shah, Ritu
    Boerner, Scott Anthony
    Li, Jing
    Durecki, Diane E.
    Drappatz, Jan
    Collichio, Frances A.
    Puduvalli, Vinay K.
    Lieberman, Frank S.
    Gonzalez, Javier
    Giglio, Pierre
    Bao, Xun
    Ivy, S. Percy
    Bindra, Ranjit
    Omuro, Antonio Marcilio Padula
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A)
    Simpkins, Fiona
    Nasioudis, Dimitrios
    Wethington, Stephanie L.
    Martin, Lainie P.
    Tanyi, Janos Laszlo
    Latif, Nawar A.
    Torigian, Drew A.
    Omran, Dalia K.
    Rodriguez, Diego
    Smith, Simon
    Dean, Emma
    Domchek, Susan M.
    Drapkin, Ronny
    Shih, Ie-Ming
    Brown, Eric J.
    Hwang, Wei-Ting
    Armstrong, Deborah Kay
    Gaillard, Stephanie
    Giuntoli, Robert Lawrence, II
    Liu, Joyce F.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)
    Lee, J-M.
    Annunziata, C. M.
    Houston, N.
    Kohn, E. C.
    Lipkowitz, S.
    Minasian, L.
    Nichols, E.
    Trepel, J.
    Trewhitt, K.
    Zia, F.
    Zimmer, A. D. S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [28] A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients
    Stodtmann, Sven
    Nuthalapati, Silpa
    Eckert, Doerthe
    Kasichayanula, Sreeneeranj
    Joshi, Rujuta
    Bach, Bruce A.
    Mensing, Sven
    Menon, Rajeev
    Xiong, Hao
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (09): : 1195 - 1205
  • [29] Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations
    Molife, L. Rhoda
    Mateo, Joaquin
    McGoldrick, Trevor
    Krebs, Matthew
    Drew, Yvette
    Banerjee, Susana N.
    Nicum, Shibani
    Ranson, Malcolm
    Rustin, Gordon J. S.
    Sessa, Cristiana
    Plummer, Ruth
    Leunen, Karin
    Friedlander, Michael
    Swaisland, Helen
    Burke, Wendy
    McCormack, Peter
    Pemberton, Kristine
    Tchakov, Ilian
    Kaye, Stanley B.
    Gourley, Charlie
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] Phase I/Ib study of the PARP inhibitor olaparib (O) with carboplatin (C) in BRCA1/2 mutation carriers with breast or ovarian cancer (Br/OvCa) (NCT00647062).
    Lee, Jung-Min
    Annunziata, Christina M.
    Hays, John L.
    Noonan, Anne M.
    Minasian, Lori M.
    Zujewski, JoAnne
    Yu, Minshu
    Ji, Jiuping Jay
    Sissung, Tristan
    Houston, Nicole D.
    Kohn, Elise C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345